# Understanding *Plasmodium vivax* recurrent infections using an amplicon deep sequencing assay, PvAmpSeq, identity-by-descent and model-based classification

**Authors and Affiliations**

Jason Rosado[1,2]*, Jiru Han[3,4], Thomas Obadia[1,5], Jacob Munro[3,4], Zeinabou Traore[1], Kael Schoffer[4], Jessica Brewster[4], Caitlin Bourke[4], Joseph M. Vinetz[6,7], Michael White[1], Melanie Bahlo[3,4], Dionicia Gamboa[7,8,9], Ivo Mueller[1,4,10ɣ], Shazia Ruybal-Pesántez[4,10,11*ɣ^]

1. Institut Pasteur, Université Paris Cité, Infectious Diseases Epidemiology and Analytics G5 Unit, Institut Pasteur, Paris, France
2. Université Paris Cité, Institut de Recherche pour le Développement, MERIT, Paris, France
3. Genetics and Gene Regulation Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
4. Infection and Global Health Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
5. Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Institut Pasteur, Paris, France
6. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
7. Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
8. Laboratorio de Malaria, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru
9. Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias e Ingeniería, Universidad Peruana Cayetano Heredia, Lima, Peru
10. Department of Medical Biology, School of Medicine and Health Sciences, University of Melbourne, Melbourne, Australia
11. Vector-borne Diseases and Tropical Public Health, Burnet Institute, Melbourne, Australia

***Correspondence**

E-mail: jjrosados@gmail.com; s.ruybal@imperial.ac.uk

ɣ: Co-senior authors contributed equally to this work.
^ Current affiliations: MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK, and Institute of Microbiology, Universidad San Francisco de Quito, Quito, Ecuador

## Summary

*Plasmodium vivax* infections are characterised by recurrent bouts of blood-stage parasitemia. Understanding the genetic relatedness of recurrences can distinguish whether these are caused by relapse, reinfection, or recrudescence, which is critical to understand treatment efficacy and transmission dynamics. We developed PvAmpseq, an amplicon sequencing assay targeting 11 SNP-rich regions of the *P. vivax* genome. PvAmpSeq was validated on field isolates from a clinical trial in the Solomon Islands and a longitudinal observational cohort in Peru, and statistical models were applied for genetic classification of infection pairs. In the Solomon Islands trial, where participants received antimalarials at baseline, half of the recurrent infections were caused by parasites with >50% relatedness to the baseline infection, with statistical models classifying 25% and 25% as probable relapses and recrudescences, respectively. In the Peruvian cohort, 26% of recurrences were likely relapses. PvAmpSeq provides high-resolution genotyping to characterise *P. vivax* recurrences, offering insights into transmission and treatment outcomes.

**Keywords**: Plasmodium vivax, recurrences, relapses, microhaplotypes, genetic diversity




Graphical abstract. Created in https://BioRender.com

82 # Introduction

83 *Plasmodium vivax* causes an estimated 9.2 million cases per year and is the most widespread *Plasmodium* parasite
84 infecting humans, and is endemic in 41 countries.[1] The ability of *P. vivax* to remain in the liver as dormant hypnozoites
85 and to cause subsequent (and often multiple) blood-stage infections contributes to onward transmission and impedes
86 efforts to eliminate malaria.[2] In areas endemic for *P. vivax,* recurrent *P. vivax* infections can result from relapses but
87 also recrudescence (due to antimalarial treatment failure if the individual received treatment) or reinfections (from a
88 new mosquito bite). Distinguishing between relapses, recrudescences, and reinfections is crucial for the assessment
89 of the effectiveness of antimalarial-based control strategies and understanding *P. vivax* biology and epidemiology, but
90 remains a major challenge.

91 The WHO Global Malaria Programme has recently highlighted the importance of using more sensitive, easily
92 implemented, and reproducible tools that allow for estimating the efficacy of clinical drug trials.[3] In the case of *P. vivax*,
93 drug efficacy trials conducted in endemic areas face the challenge of establishing whether recurrent parasitemia after
94 treatment is due to treatment failure (recrudescence), relapse, or reinfection. Comparing parasite genotypes of
95 baseline infections with the ones from recurrent infections allows us to better estimate drug failure rates through
96 'molecular correction' broadly based on the identification of the same, closely related, or distinct genotypes. Unlike *P.*
97 *falciparum*, where genotyping must distinguish between recrudescences from reinfections, genotype data from *P.*
98 *vivax* recurrent infections must be able to discriminate recrudescences from both reinfections and relapses for
99 evaluation of blood-stage treatment efficacy. In addition, to evaluate the efficacy of anti-hypnozoite treatments (e.g.,
100 primaquine), it is critical to be able to resolve relapses (anti-hypnozoite treatment failure) from reinfections.
101 Classically, genotyping infections for 'molecular correction' in drug-efficacy clinical trials has been done with
102 microsatellite markers,[4] but more recently with amplicon sequencing approaches.[3,5,6] A limitation of microsatellite
103 genotyping can be the insufficient resolution to detect minority clones in infections. [7] This can result in an
104 overestimation of treatment efficacy in clinical trials as the undetected clones could be resistant parasites,
105 recrudescent clones, or relapsing hypnozoites not detected at baseline.

106 The sequencing of Single Nucleotide Polymorphism (SNPs) or SNP-rich amplicons by next-generation sequencing
107 approaches (Amplicon deep sequencing or AmpSeq) has been shown to overcome the drawbacks of microsatellites.[8]
108 For example, i) detection of multiple SNPs in the same read allows direct detection of haplotypes, ii) sufficient
109 sensitivity to detect minor clones and track clone dynamics over time in *Plasmodium* infections,[7,9–11] and iii) high

110 reproducibility. For *P. falciparum,* AmpSeq genotyping has been shown to improve the classification of recrudescence
111 and reinfections in clinical trials.[5,12]

112 In addition to their use for evaluation of treatment efficacy, AmpSeq markers are also being used to identify imported
113 malaria cases,[13] estimate transmission levels in population studies,[14] detect drug-resistant parasites,[14–19] and
114 characterise *Plasmodium* population genetics[18,20–25]. In addition, *P. vivax* genome-wide panels of Ampseq markers and
115 Molecular Inversion Probes (MIPs) have recently been developed for population genetics, geographic origin
116 assignment, and detection of SNPs associated with resistance.[6,18,26–30] In a recent study by Kleinecke and colleagues, a
117 panel of 93 genome-wide AmpSeq microhaplotypes was applied in a clinical trial to classify 108 primary and recurrent
118 infection pairs using identity-by-descent (IBD) estimates.[6] The study showed a higher frequency of suspected relapses
119 or recrudescence (high IBD) (84%) in patients treated with primaquine compared to those without primaquine (60%).

120 To advance our understanding of *P. vivax* recurrent infections, we developed a *P. vivax* AmpSeq (PvAmpSeq) assay
121 that targets 11 highly polymorphic SNP-rich regions or microhaplotypes (across 11 chromosomes) and applied several
122 recently developed approaches for studying infections at the clone level using IBD and probabilistic models. Here, we
123 show the validation of PvAmpSeq for two applications: on samples from a clinical trial where genetic classification of
124 recurrent infections is necessary for molecular correction of drug failure rates and from a community cohort where
125 genetic classification is useful to understand *P. vivax* epidemiology and transmission patterns. We used samples from
126 the ACT-Radical randomised-controlled clinical trial conducted in the Solomon Islands between 2018 and 2019,
127 involving patients receiving three different drug combinations, with the overall aim to test for potential antagonistic
128 effects of the drug combinations (James, Obadia *et al*. *under review*). Two of the trial arms included drug combinations
129 involving the anti-hypnozoite antimalarial drug primaquine (PQ), where patients were treated to clear both blood-
130 stage parasites and hypnozoites at baseline. We also used samples from an observational longitudinal cohort
131 conducted in the Loreto region in the Peruvian Amazon, where individuals were followed up between December 2014
132 and December 2015.[31] We processed PvAmpSeq sequencing data using the AmpSeqR R package to demultiplex and
133 analyse AmpSeq data[32] and used various approaches for genetic classification of recurrent infections. Overall, our
134 findings point to the potential for PvAmpSeq to provide important insights about recurrent infection dynamics in both
135 clinical trials and epidemiological studies.

# Methods

**Ethics**

Ethical approval for the Solomon Islands ACT-Radical clinical trial was obtained from the Solomon Islands Health Research and Ethics Review Board (HRE 041-16) and the Walter and Eliza Hall Institute of Medical Research Human Research Ethics Committee (WEHI 16-08). The Peruvian cohort was approved by the Institutional Ethics Committee from the Universidad Peruana Cayetano Heredia (UPCH) (SIDISI 57395/2013) and from the University of California San Diego Human Subjects Protection Program (Project # 100765). UPCH also approved the use of the DNA samples of *Plasmodium vivax* infections at the Institut Pasteur (SIDISI 100873/2017).

**Study sites and samples**

Samples from the Solomon Islands were collected as part of the ACT-Radical clinical trial (registered under Australia and New Zealand Clinical Trials Registry ANZCTR 12617000329369) conducted between September 2017 and February 2019. Briefly, 374 individuals were enrolled in the study, 82% (307/374) of participants had a primary symptomatic *P. vivax* infection confirmed by qPCR and were treated with artemether-lumefantrine (AL), AL plus primaquine (AL+PQ), or dihydroartemisinin-piperaquine plus primaquine (DP+PQ). Of these, 307 individuals were actively followed for up to 168 days or until a recurrent *P. vivax* infection was confirmed either by light microscopy or qPCR. 191 individuals had *P. vivax* recurrent infections confirmed by light microscopy or qPCR. Of the positive blood samples, 218 (from 91 participants) were available for PvAmpseq evaluation. Blood samples were collected in EDTA tubes for the baseline infections (n = 91), whereas recurrent infection samples were collected as dried blood spots (DBS) (n = 137).

Details on the Peruvian cohort have been previously reported.[31,33] Briefly, a three-year-long observational cohort study was conducted in Peru from December 2012 to December 2015 in two Amazonian villages in the Loreto Region: San José de Lupuna and Cahuide.[33] Using home-to-home and community-based screening, volunteers ≥ 3 years old were invited to participate in this cohort. Between December 2014 and December 2015, 1083 out of 7612 blood samples (14.2%) were positive for *P. vivax* by qPCR. Of these positive samples, 449 DNA *P. vivax* positive samples (from 176 participants) were available at Institut Pasteur for genomic studies. As these samples were originally diagnosed by SYBR Green-based qPCR methods and most of them had low parasite density infections (1.55 parasites/µL (IQR: 0.74–8.38)),[31] we performed a diagnostic Taqman qPCR to downselect amplifiable samples. This selection resulted in 274 DNA samples from 152 participants with at least 1 qPCR positive result for *P. vivax* in the last 12 months of follow-up (1 *P. vivax* infection = 65 participants, 2 *P. vivax* infections = 56 participants, 3 *P. vivax* infections = 24 participants, 4 *P. vivax* infections = 6 participants).

165 All cohort participants provided written informed consent for participation in both studies. Parental written consent
166 and assent were obtained in the case of participants <18 years in the Peruvian cohort.

167 **DNA extraction and qPCR**

168 In the Solomon Islands ACT-Radical clinical trial, whole blood samples from participants at baseline were collected in
169 EDTA tubes and conserved at -20°C until DNA extraction. Genomic DNA was extracted from 200 µL of whole blood
170 using the Favorprep 96-well genomic DNA kit (Favorgen, cat # FADWE 96004, Taiwan) and following the
171 manufacturer's recommendations. PBS buffer was added to the samples with insufficient volume (< 200 µL). Dried
172 blood spots (DBS) from participants with recurrent infections were collected onto filter paper and let dry at room
173 temperature. DBS samples were conserved at -20°C until DNA extraction. DBS samples were cut into 6mm diameter
174 bloodspot discs using a hole punch. Five bloodspot discs per sample were utilised for DNA extraction using Favorprep
175 96-well genomic DNA kit (Favorgen, cat # FADWE 96004, Taiwan). Genomic DNA from whole blood and DBS was eluted
176 in 50 µL of elution buffer and stored in 96-well plates at -30°C until their use.

177 In the Peruvian cohort, blood samples were collected by finger prick onto filter paper and left to dry at room
178 temperature. DNA was isolated from DBS using the E.Z.N.A. Blood DNA Mini Kit (Omega Bio-tek, Inc., Norcross, GA,
179 US), and molecular diagnosis was performed using the Mangold method.[34,35]

180 For parasite density quantification, we performed a duplex TaqMan qPCR assay combining specific primers and probes
181 targeting the *18s rRNA* gene region for *P. falciparum* and *P. vivax* in a duplex reaction, as reported by Rosanas-Urgell
182 A *et al*., with slight modifications.[36] The reaction was prepared in a total of 13 µL containing 1X GoTaq® Probe qPCR
183 Master Mix (Promega, USA), 769 nM of forward and reverse primers, 384 nM of probe, 1.5 µL of Nuclease-free water,
184 and 2 µL of DNA sample. The PCR conditions consisted of an initial denaturation at 95 °C for 2 min, followed by
185 amplification for 45 cycles of 15 s at 95 °C and 1 min at 58 °C. The assay was run in a QuantStudio TM 5 Real-Time PCR
186 system (Applied Biosystems, USA). The number of copies of 18s rRNA DNA/µL of DNA was determined by using a
187 standard curve from a sevenfold serial dilution to 1:10 of a plasmid at concentrations of $1 \times 10^5$ copies/µL down to 1
188 copy/µL in nuclease-free water. Samples with late amplification (Cq value >40 & <44; <1 copy/µL) were confirmed by
189 an extra run. *P. vivax* and *P. falciparum* primers and probes detect 3 copies of 18s rRNA DNA per genome. This implies
190 that a concentration of 5 copies/µL in a sample is equivalent to approximately 1-2 parasites/µL.

191 **Marker selection and primer design**

192 A panel of highly informative amplicons was designed based on whole genome sequencing data from the MalariaGEN
193 *Plasmodium vivax* Genome Variation Project accessed in June 2018 (PvGV).[37] Briefly, FASTQ files were downloaded
194 from the SRA, and SNP/indel variant calling was performed according to GATK V4 best practices against the PvP01
195 reference genome. Of the 354 samples processed, 154 were excluded due to low coverage (< 5x median coverage),
196 high SNP missingness (>10%), multi-clonality checks (Fws < 0.85) or being from a country with too few samples
197 remaining (< 15), leaving 200 samples over 6 countries (Cambodia, Colombia, Mexico, Papua New Guinea, Peru and
198 Thailand). Genomic regions were then excluded based on the coverage distribution across remaining samples as
199 follows: the genome was divided into 1000 bp bins, and coverage was assessed with samtools bedcov[38] for both high
200 mapping quality (HMQ, mapping quality >= 30) and low mapping quality (LMQ, mapQ <= 30) reads. Coverage was then
201 normalised within samples by dividing by the sample median HMQ coverage. Genomic regions were then excluded if
202 the median across samples was greater than 1.5 or less than 0.5 or if the median proportion of HMQ coverage was
203 less than 0.5. This method resulted in the exclusion of the majority of the hypervariable sub-telomeric regions of
204 PvP01. The remaining genome was then searched for all regions that contained at least 4 SNPs within 140 bp, with
205 primer design attempted using Primer3[39] with an optimal length of 22 bp and optimal melting temperature of 60 °C,
206 avoiding SNPs and indels in the primer region.

207 **Pv AmpSeq assay**

208 The PvAmpSeq assay amplifies 11 SNP-rich regions, or microhaplotype markers, located across 11 chromosomes.
209 Detailed protocols are described in Text S1. Briefly, AmpSeq libraries were prepared after amplification using a nested
210 PCR strategy. Due to the low parasitemia of *P. vivax* infections frequently found in field samples, parasite genomic
211 regions encompassing marker-specific sites were enriched by multiplex primary PCRs (pPCR) with 25 cycles of
212 amplification. Individual secondary nested PCRs (nPCR) were performed using marker-specific primers with an
213 overhang sequence in the 5' end and 25 cycles, enabling multiplexing of amplicons per sample. nPCR products were
214 purified, quantified, and normalised at 15 ng/µL using QIAGEN MinElute 96 UF PCR Purification Kit (QIAGEN, Germany)
215 and Quant-iT PicoGreen® dsDNA kit (Thermo Fisher Scientific, USA), respectively. Normalised nPCR products were
216 pooled and performed index PCR (iPCR) using long fusion primers with P5/P7 adapters, index and overhang sequences
217 in the backbone (Text S1), limited to 10 PCR cycles.

218 iPCR products were quantified and normalised at 20 ng/µL, then combined into pools of equal molarity. Long fusion
219 primers (<200 nt) and long non-specific PCR products (>400 nt) were removed from the final library by double size

220 exclusion using 0.55 and 0.25 volumes of NucleoMag® NGS beads, respectively (Macherey-Nagel, Germany). Each pool
221 was normalised to 10 nM and combined into a final sequencing library. Correct amplicon sizes in library pools were
222 confirmed by Agilent D5000 ScreenTape System (Agilent Technologies, USA). The final library was sequenced on an
223 Illumina MiSeq platform in paired-end mode using the MiSeq reagent kit v3 (600 cycles; 2 × 300 bp) with 15% spike-in
224 of Enterobacteria phage *PhiX* control v3 (Illumina) at the Walter and Eliza Hall Institute Genomics Core (Melbourne,
225 Australia).

226 **Analysis of assay sensitivity: Serial dilution of samples and mock mixed infections**

227 The dynamic range and limit of detection of AmpSeq markers were estimated by two approaches: i) serial dilution of
228 one clinical *P. vivax* sample at 802, 80.2, 40.1, 8.02, 4.01, 0.8 parasites/µL, and ii) evaluating the detection of minority
229 clones in mock mixed infections. We considered a marker successfully sequenced when it had >100 reads per sample.
230 We determined the last sample dilution detected by the assay as the last sample with at least 7 of 11 successfully
231 sequenced markers (40% of missingness). Samples with fewer than 7 of 11 successfully sequenced markers were
232 filtered out due to low-quality amplification.

233 To determine the limit of detection of minority clones of the PvAmpSeq assay, we performed AmpSeq on mock mixed
234 *P. vivax* infections. Two monoclonal *P. vivax* DNA isolates confirmed by whole genome sequencing from the Solomon
235 Islands trial were mixed in different proportions: 1:1, 1:10, 1:50, 1:100, 1:500, 1:1000, 10:1, 50:1, 100:1, 500:1, 1000:1
236 and sequenced at all 11 markers. We also evaluated the detection of minority clones by artificially creating mixed
237 infections from sequencing data using the Biostrings[40] and ShortRead[41] R packages. We generated artificial amplicon
238 datasets from a sub-selection of the raw FASTQ sequences generated in this study from 14 monoclonal *P. vivax*
239 samples sequenced at the 11 markers. We created artificial sequence data for each marker with known MOI and clone
240 mixture proportions by randomly selecting the sequence from two samples with 10 different mixture proportions
241 (0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 20%, and 50%) and 7 different read counts (100, 200, 500, 1000, 2000, 5000,
242 and 10000). For read counts of 100, 200, and 500, the mixture proportion started at 1% because we could only extract
243 the integer sequence from two samples. For each marker, we only artificially mixed two samples of distinct
244 microhaplotypes and non-missing reads. Additionally, to generate more realistic amplicon datasets, we also created
245 artificial sequence data that reflected random sampling error by utilising binomial sampling with 10 different
246 probabilities (mixture proportions, as above) and 7 different read counts (as above) and repeated this 50 times. We
247 then randomly selected 20 combinations of two distinct samples from each marker.

248 **Sequencing read analysis and haplotype calling**

249 Sequencing reads were analysed using the R package AmpSeqR version 0.1 (https://github.com/bahlolab/AmpSeqR)[32].
250 Sequencing reads were demultiplexed by sample and by amplicon. The overlapping sequences of paired reads were
251 merged, and samples with a read coverage of < 1,000 reads per sample were excluded from the analysis. Index,
252 overhang sequences, and primer sequences were removed by trimming from the forward and reverse reads. In this
253 study, a microhaplotype was defined as an amplicon sequence variant at a given locus. The minor allele frequency
254 (MAF) was calculated for each single nucleotide in the given dataset, and then SNPs below 0.1% in frequency were
255 removed to exclude PCR and sequencing errors. In microhaplotypes resulting from insertion and deletion (indels), such
256 as homopolymer regions (>3 repeated bases based on the reference sequence, e.g., "AAAA"), the sequence was
257 adjusted to have the reference number of repeats, as the high rate of indels and errors in homopolymer regions.
258 Microhaplotypes with low sequence identity to the *P. vivax* P01 reference genome (<75%) or with a frequency < 1%,
259 and chimeric and singleton reads were excluded from further analysis. Microhaplotype calling required a minimum of
260 5 reads coverage per locus, a within-host haplotype frequency of ≥ 1%, and an occurrence of this microhaplotype in ≥
261 2 samples over the entire dataset. All amplicon sequencing data are available under accession no. SAMN43387238 to
262 SAMN43387533 at the Sequence Read Archive (SRA), and the associated BioProject ID is PRJNA1153071.
263 Microhaplotype sequences were also deposited in the open-access Github repository:
264 https://github.com/jrosados/PvAmpSeq.

265 **Population-level and within-host diversity estimates**

266 The expected heterozygosity ($H_e$) was calculated for each locus in the given dataset as described elsewhere.[42] The
267 within-host microhaplotype frequency was calculated as the number of reads per microhaplotype per locus over the
268 sum of all reads per locus in a sample. Multiplicity of infection (MOI) was calculated as the highest number of distinct
269 microhaplotypes per locus across all loci in a given sample.

**Reproducibility of AmpSeq data and comparison with available microsatellite data**

As part of the optimisation of PvAmpSeq, we leveraged the availability of two sample types from the Solomon Islands ACT-RAD clinical trial: red blood cell pellets and dried blood spots from the same individual collected at the baseline visit. We compared the microhaplotype marker coverage and MOI estimates for 17 available paired sample types from the baseline.

In addition, five DNA samples from the Peruvian cohort had matched microsatellite genotyping data based on 16 markers published by Manrique *et al*.[43] We also compared the PvAmpSeq MOI data with MOI estimates based on microsatellite data.

**Classification of samples into homologous and heterologous**

We used the *dcifer* R package to calculate identity-by-descent (IBD) IBD r^ and the IBD r^total (i.e., inferred shared ancestry) between polyclonal infections using a statistical framework for inference that accounts for the complexity of infection (COI) and population-level allele frequencies (in our case, microhaplotype frequencies).[44] Briefly, we first estimated naive COI, and then population-level haplotype frequencies were adjusted for the estimated COI based on our data. *Dcifer* provides estimates of r^, the relatedness between two samples, and performs a likelihood-ratio test to test the null hypothesis that two samples are unrelated (H0: r^ or IBD = 0) at a significance level of $\alpha = 0.05$, adjusted for a one-sided test. For all pairs of related samples where we reject the null hypothesis, this provides statistical confidence that two pairs of samples are significantly related. In addition, in the case of samples with COI>1 we also estimate both *M'*, which is the number of related *clone* pairs between both samples, and $r\hat{}_{total}$, which represents the 'total' or overall relatedness between all clones. However, the method assumes there is no within-host relatedness between clones in an infection, which is violated in our case due to the possibility of genetically related relapses being present in our samples. Based on IBD estimates, infections were classified as heterologous (IBD: 0-0.25), difficult to define (IBD: 0.25-0.5), and homologous (IBD: 0.5-1).

**Classification of samples into relapse, recrudescence, and reinfections**

We used the recently developed *Pv3Rs* R package (https://github.com/aimeertaylor/Pv3Rs), which uses a probabilistic model-based classification framework to classify recurrent *P. vivax* infections as recrudescence, relapse, or reinfections based on genetic data.[45] The model accounts for IBD of parasite clones between recurrent episodes, COI, and population-level allele frequencies (in our case, microhaplotype frequencies) within a Bayesian framework based on informative prior probabilities for each recurrence classification state. In addition, the model estimates both marginal and joint probabilities of the different recurrence states (recrudescence, relapse, and reinfection). Marginal

probabilities provide the likelihood of each recurrence state occurring independently, while joint probabilities consider the combined likelihood across multiple episodes within an individual. Marginal probability outputs from the model may be more reliable, particularly in scenarios where model assumptions may be violated.[45]

For the Solomon Islands clinical trial samples, where participants received treatment at baseline, we applied the default prior probabilities of 0.33 for each recurrence classification state. This approach assumes that recrudescence is a possible outcome given the treatment administered at the start of the study. In contrast, for the Peru cohort, which was an observational community study without baseline treatment, we assigned prior probabilities of 0.10 for recrudescence and 0.45 each for relapse and reinfection states. These values reflect the assumption that most recurrences in this setting are likely due to relapse or reinfection rather than recrudescence. To estimate population-level microhaplotype frequencies, we used only the subset of baseline samples for the Solomon Islands clinical trial samples but all samples for the Peru cohort. In the case of the Solomon Islands, we opted for this approach to minimise the potential bias from within-host selection of recrudescent parasites, which might distort microhaplotype frequency estimates if post-treatment samples were included. In the Peru cohort, we used all samples to provide a broader representation of the circulating parasite population because most recurrences are presumed to be reinfections or relapses (both drawn from the broader mosquito population).

We performed a series of sensitivity analyses to better understand the limitations of Pv3Rs and the potential impact on our results. First, we explored the impact of inclusion/exclusion of samples for estimation of population-level microhaplotype frequencies in the case of the Solomon Islands cohort and used all samples (baseline and follow-up) to estimate population-level microhaplotype frequencies, which did not impact the classification of samples. We also ran a sensitivity analysis to estimate the false discovery rate (FDR) of relapses and recrudescences by performing a simple simulation of infection pairs using our sequence data. We randomised infection pairs (i.e., selecting entire 'infection sets' of microhaplotypes and randomly pairing them to another infection set), ensuring that pairs were not derived from the same participant and imposing a time order such that the recurrent infection always occurred after the first infection. This generated a 'null' distribution under the simple assumption that such randomly paired infections should not represent relapses or recrudescences. In the Solomon Islands dataset, we randomised baseline samples with follow-up samples, and in the Peru dataset, we randomised all samples. FDR was then calculated as the proportion of infections 'misclassified' as relapses or recrudescences out of all infection pairs under this null model. We ran 100 replicates for each cohort and calculated the mean FDR and 95% confidence interval. Finally, to assess

how particular microhaplotypes might influence the probabilistic classification, e.g., due to heterozygosity or number of alleles in the population, we iteratively re-ran the analysis, omitting one marker each time.

**Statistical analysis and data accessibility**

Categorical variables were compared using the two-sided Fisher's exact test or χ2 test when required. Continuous covariates were compared using two-sided Mann-Whitney, Kruskal-Wallis, or T-test when required. Relationships between parasite density and read counts were tested using the Pearson correlation coefficient, and *p-values* were adjusted by the Benjamini-Hochberg method. All statistical analyses were performed using R 4.1.0 (https://www.r-project.org/). Original data, R scripts, and algorithms developed in this study are accessible in the repository https://github.com/jrosados/PvAmpSeq. The sample and patient IDs of the original databases were not known to anyone outside the research group. De-identified datasets were generated during the current study and used to make all figures available as supplementary files or tables.

356 # Results

357 **PvAmpSeq microhaplotype marker selection**

358 Of the 354 samples processed from PVGV, 200 high-quality WGS sequences from 6 countries (Cambodia, Colombia,
359 Mexico, Papua New Guinea, Peru, and Thailand) were searched for all regions that contained at least 4 SNPs within a
360 window of 140 bp. All successful polymorphic regions were then ranked by expected heterozygosity within each
361 country, with the highest mean-ranked microhaplotype being selected for each of the 14 chromosomes (Figure S1).
362 Although we excluded the majority of the hypervariable sub-telomeric regions of PvP01, microhaplotypes from Chr06
363 and Chr12 were selected but then excluded during the PCR optimisation as they were located in the proximity of
364 hypervariable sub-telomeri*c pir* genes. Chr04 was excluded due to the low amplification success in Solomon Islands
365 samples. Our panel included 11 microhaplotype markers or loci across 11 chromosomes.

366 The final panel of PvAmpSeq microhaplotype markers comprised three loci encoding highly polymorphic surface
367 antigens such as Merozoite Surface Protein 1 (MSP1, Chr07, PVP01_0728900), Merozoite surface protein 3 (MSP3.3,
368 Chr10, PVP01_1031500) and Apical Membrane antigen 1 (AMA1, Chr09, PVP01_0934200); proteins involved in
369 reticulocyte invasion, Reticulocyte binding protein 2a (RBP2a, Chr14, PVP01_1402400); enzymes such as Protein
370 Tyrosine phosphatase putative (PTP2, Chr01, PVP01_0113700), Glyoxalase I-like protein (GILP) putative (Chr11,
371 PVP01_1144200); pseudogenes like Lysophospholipase putative (Chr02, PVP01_0201300); and putative proteins of
372 unknown function such as STP1 protein (Chr05, PVP01_0533300), conserved *Plasmodium* protein (Chr03,
373 PVP01_0302600 and Chr13, PVP01_1346800) and *Plasmodium* exported protein (Chr08, PVP01_0838000). These
374 genes contain both SNPs and indels (Text S2).

375 **Validation on samples from two cohort studies**

376 A total of 492 (Solomon Islands, n = 218; Peru, n = 274) samples were sequenced for the validation of the PvAmpSeq
377 assay. 196 samples were filtered out due to a low number of reads (<1,000 reads per sample) or low identity sequences
378 (Solomon Islands, n = 71; Peru, n = 125). Discarded samples had a median parasite density of 14.4 parasites/uL of DNA
379 [IQR: 5.63- 39.5]. Additionally, samples with more than 40% (5 out of 11 loci) of missingness were discarded (Peru, n
380 = 9), as well as ten samples from the Solomon Islands trial, due to sequencing failure of their paired baseline infection.
381 Negative DNA samples and negative template controls included in sequencing runs yielded <100 reads and were
382 filtered out.

383 The remaining 275 samples selected for downstream analysis corresponded to 77 participants from the Solomon
384 Islands and 93 participants from Peru. Of the Solomon Islands participants, 41 had available samples from 1 up to 6

recurrent infections (total 58 samples), whereas only 40 Peruvian participants had follow-up samples, corresponding to 1 or 3 recurrent infections (total 47 samples). The median age of the participants was 10.1 years [IQR: 7.42-14.4] and 36.7 [18.0-51.5] for the Solomon Islands and Peru, respectively (Table 1). There was no significant difference between the parasite density of baseline and follow-up infections for both cohorts ($p > 0.05$). As expected for the clinical trial, febrile infections were more frequent at the baseline of the Solomon Islands cohort ($p < 0.05$).

**Table 1.** Epidemiological characteristics of participants and description of their infections

| **Participant characteristics** | **Solomon Islands**<br>**n = 77** | **Peru**<br>**n = 93** |
|---|---|---|
| Age, median [IQR] | 10.1 [7.42-14.4] | 36.7 [18.0-51.5] |
| Sex, number female (%) | 32 (41.6%) | 51 (54.8%) |
| Treatment administered | Artemether-lumefantrine (n = 21), artemether-lumefantrine + primaquine (n = 25), dihydroartemisinin-piperaquine + primaquine (n = 31) | Chloroquine-primaquine (n=1) |
| **Infection characteristics** | **n = 135** | **n = 140** |
| Parasite density, median [IQR] | | |
| Baseline | 416 parasites/µL [81.7-793][a] | 341 parasites/µL [40.6-8560][b] |
| Follow-up | 151 parasites/µL [18.1-978] | 337 parasites/µL [77.6-1470] |
| Febrile, number (%) | | |
| Baseline | 38/77 (49.4%)[c] | 7/93 (7.5%)[d] |
| Follow-up | 11/58 (19.0%) | 2/47 (4.3%) |

a Statistical difference between baseline and follow-up assessed by a two-sided Mann-Whitney test, $p = 0.2515$.
b Statistical difference between baseline and follow-up assessed by a two-sided Mann-Whitney test, $p = 0.7541$.
c Statistical difference between baseline and follow-up assessed by a two-sided Fisher's exact test, $p = 0.0003$.
d Statistical difference between baseline and follow-up assessed by a two-sided Fisher's exact test, $p = 0.7178$.

**Data processing and read coverage**

Reads were demultiplexed and filtered using AmpSeqR[16]. After discarding PCR artefacts, the rate of success per loci went from 0.70 to 1 (Table S1). The median success rate in follow-up samples was slightly lower than baseline samples but still around 0.90 for both cohorts (Solomon Islands; baseline median: 0.99[IQR: 0.97-1.00], vs follow-up median: 0.91[0.91-0.95], $p < 0.05$; Peru; baseline median: 0.98 [0.80-0.98], vs follow-up median: 0.89 [0.82-0.93], $p > 0.05$).

The median read coverage per sample was 4309 [2051-8129] and 4752 [2535.5-7524] for the Solomon Islands and the Peruvian cohort, respectively. Chr07 had the highest median read coverage per sample in both cohorts (9774, [4672.2-9964] for the Solomon Islands and 8734 [5560.5-9857.2] for Peru), whereas Chr01 had the lowest median coverage read (1763 [960-2326] in the Solomon Islands; and 2376 [1606-4180] in Peru) (Figure 1A).

400 No significant correlation was found between the sample parasite density (parasite/µL) and the number of reads per
401 marker (Pearson's r range = -0.23-0.16, *adjusted p* range = 0.17-0.94) (Figure 1B). Samples with <10 parasites/µL were
402 amplified with variable read coverage per marker (median: 4590 [2574-8499]). The high variance seen in each parasite
403 density group suggested that the DNA quality affected the amplification performance. On the other hand, detection
404 of a control sample (AR-246) was possible only when parasite density was >40 parasites/µL. Microhaplotypes were
405 detected at dilutions of 40.1, 80.2, and 802 parasites/µL for the control sample (Figure 1C). Control sample dilutions
406 with ≤ 8.02 parasites/µl were poorly sequenced for most of the loci (< 60 reads). Chr13 did not successfully amplify in
407 the control sample and was precluded from this analysis. We detected one microhaplotype per locus in the AR-246
408 control sample for all dilutions, except at the highest dilution of 802 parasites/µL, where two microhaplotypes were
409 detected in marker Chr09, one of which had a very low microhaplotype frequency (0.018) (Figure S2). This
410 microhaplotype could be a true microhaplotype since it was also detected in other samples in this dataset and with
411 high frequency. This indicates that, as expected, higher parasite densities can more accurately determine the
412 complexity and diversity of sample infections.




413
414 **Figure 1.** Marker coverage and sample parasite density. (A) Number of reads per marker on field samples. (B) Number of reads and parasite
415 density of field samples. (C) Limit of detection for parasite density; in blue: markers that passed the quality control step; in grey: markers that
416 failed the quality control step; empty bars: markers with no successful PCR amplification.

417 **Limit of detection for minority clones**

418 Two monoclonal samples from the Solomon Islands trial were selected to mimic a mixed infection (AR079 and AR093).
419 DNA samples were normalised at 100 parasites/µL and combined in the following ratios: 1:1, 1:10, 1:50, 1:100, 1:500,
420 1:1000, 10:1, 50:1, 100:1, 500:1, and 1000:1. In Figure 2A, the results of the mock mixed infections are shown. Analyses
421 were restricted to informative AmpSeq markers with distinct microhaplotypes between samples, i.e., Chr01, Chr02,

422 Chr03, Chr05, Chr09, and Chr14. Markers Chr07, Chr08, Chr10, and Chr11 were not included because both samples
423 had the same microhaplotype in these loci. The correct minor microhaplotype was detected in most mixtures only at
424 1:1 (50%), 1:10 (10%), and 10:1 (10%) mixture proportions for Chr01, Chr02, Chr09, and Chr14, and the mixture
425 proportion was not the same as the defined mixtures. Only microhaplotypes from the major clone were detected in
426 most samples. We examined the minor clone sequences for each sample in the raw sequence data and found that the
427 minor clone sequence coverage was extremely low (less than 5 reads compared to over 20,000 reads in total), which
428 resulted in the inability to detect the minor clones. A possible reason is that the mixture experiment is based on field
429 samples. Minority clones at 2% (1:50) were detected for Chr02. Minority clones were not detected for Chr05 and
430 Chr03. In some samples, we detected singleton microhaplotypes with very low frequencies that were not AR-079 or
431 AR-093 microhaplotypes, which would represent false positives (Figure S3). We compared the microhaplotype
432 sequences of major and minor microhaplotypes in these samples and found that these minor and major
433 microhaplotypes differed in only one position. These microhaplotypes are likely to be systematic sequencing errors,
434 with the base-call errors generally occurring at the same genomic position from different sequence reads.[46] Systematic
435 errors are often mistaken for heterozygous sites in individuals or SNPs in population analysis.

436 We also examined the limit of detection of artificially mixed infections by determining the minor clone detectability
437 success *in silico*. At the highest read counts (5,000 and 10,000), the minor clone was robustly detected at a clone
438 relative frequency as low as 0.5% up to 50% for all amplicon markers; however, when read counts were <1,000, the
439 minor clone was only detected accurately when the relative frequency was >10% (Figure 2B). Regardless of the data
440 being generated with the same mixture ratios and read counts, there were substantial differences in the detectability
441 of the minor clone based on the microhaplotype marker. For example, at a read count of 10,000 and minor clone
442 relative frequency of 0.1%, three markers had 100% success in detecting the minor clone (Chr03, Chr07, and Chr10),
443 but there were very low success rates for markers Chr01, Chr08, Chr11, Chr13, and Chr14 ranging between 0% to 29%.
444 We also created the artificially mixed infections following a binomial distribution to reflect a more realistic random
445 sampling error and found similar results as above (Figure S4). We thus set 2% as the lower limit of detection for
446 minority clones of PvAmpSeq and recommend at least 10,000 reads per microhaplotype amplicon for robust minor
447 clone detection (assuming frequency may be as low as 0.1%). If the minor clone relative frequency is expected to be
448 around 10%, we recommend at least 1,000 reads.




**Figure 2.** Detection of minority clones in mock and artificial mixed infections. (A) The Y-axis shows the sample ratios detected in mock mixed infections. The X-axis shows the markers grouped by expected sample ratios in mock infections (1:1, 1:10, 1:50, 1:100, 1:500, 1:1000, 10:1, 50:1, 100:1, 500:1 and 1000:1). In blue: clones from sample AR079; in yellow: clones from sample AR093; in red or orange: contaminants clones. expec: expected results from mocked mixed infections. Markers sharing the same microhaplotypes between samples are not displayed. (B) The detectability of the minor clone under different numbers of reads and artificial mixture ratios. The X-axis represents the mixture dilutions (%), and the Y-axis represents the success rate (%) of detecting the minor clone. Coloured by amplicon marker.

## Exploring population and within-host genetic diversity metrics using PvAmpSeq

The microhaplotype markers had high diversity in both sample sets, with the mean expected heterozygosity ($H_e$) of the 11 markers 0.70 for the Solomon Islands samples and 0.65 for the Peruvian samples. We found approximately half of the markers had high $H_e \geq 0.70$ (7/11 markers in the Solomon Islands; 5/11 markers in Peru), but the markers with the highest heterozygosity differed in each cohort except for Chr05 and Chr07 that had high $H_e$ in both (Figure 3A) but different microhaplotype frequencies (Figure 3B). The remaining markers had low- to moderate- heterozygosity, ranging from 0.29 to 0.69 (Figure 3A). High diversity markers ($H_e \geq 0.70$) had a median of 7 alleles (range: 4-43) and 13 microhaplotypes (range: 5-13) in the Solomon Islands and a median of 6 alleles (range: 3-34) and 7 microhaplotypes (range:5-7) in Peru (Table S2).




**Figure 3.** Genetic diversity of markers and multiplicity of infection of validation samples. (A) Markers were sorted by descending $H_e$. He: Expected heterozygosity calculated as the number of microhaplotypes per marker divided by microhaplotype frequency on Solomon Islands (n = 135) and Peruvian samples (n = 140). The number of microhaplotypes per marker is indicated on top of each bar. (B) Microhaplotype frequency per marker estimated on the Solomon Islands and Peruvian samples. Each colour indicates a different microhaplotype. (C) Estimated multiplicity of infection (MOI) in field samples as the highest number of distinct microhaplotypes by all markers. The Y-axis shows the within-host frequency of microhaplotypes per sample, calculated as the percentage of microhaplotype reads per sample. The X-axis shows the samples sorted by estimated MOI. Every sample is represented by a vertical bar. (D) Distribution of MOI in paired samples, where Day 0 represents the baseline infection (Solomon Islands, n = 41; Peru, n = 40) and Day X the day of recurrent infection (Solomon Islands, n = 58; Peru, n = 47).

Using the highest number of distinct microhaplotypes detected by all markers, we estimated the multiplicity of infection (MOI) in both cohorts. Out of 135 samples in the Solomon Islands cohort, 59 had a maximum MOI = 1, 60 samples had a maximum MOI = 2, 13 samples had MOI = 3, and 3 samples had MOI = 4 (Figure 3C). In the Peruvian cohort, out of 140 samples, 62 had a maximum MOI = 1, 69 samples had a maximum MOI = 2, and 9 samples had MOI = 3 (Figure 3C). No association was found between the maximum MOI obtained in the baseline samples and participant's age (Kruskal-Wallis test, Solomon Islands $p$ = 0.986, Peru $p$ = 0.672; Figure S5), nor with the presence of fever ($\chi 2$ test, Solomon Islands $p$ = 0.744, Peru $p$ = 0.823; Figure S6). There was no significant difference in MOI at baseline compared to follow-up in either cohort (Solomon Islands, baseline mean MOI = 1.83 vs follow-up mean MOI = 1.74, two-sided Mann-Whitney test, $p$ = 0.5997; Peru, baseline mean MOI = 1.62 vs follow-up mean MOI = 1.62, two-sided Mann-Whitney test, $p$ = 0.9244) (Figure 3D, Table S3). To test whether participants with polyclonal infections at baseline had faster times to recurrence than those with monoclonal infections at baseline, we compared the time to first recurrent infection of paired samples stratified by MOI (MOI = 1 vs MOI ≥ 2). In both cohorts, polyclonal baseline infections (MOI ≥ 2) had comparable times to first recurrent infection to monoclonal baseline infections (MOI = 1)

487 (two-sided Mann-Whitney test, Solomon Islands $p = 0.7555$, Peru $p = 0.0635$). Likewise, the time to the next recurrent
488 infection was not affected by the change of MOI between recurrent infections (Kruskal-Wallis test, Solomon Islands $p$
489 $= 0.3979$, Peru $p = 0.4724$; Figure S7).

490 As part of the assay validation, we used available microsatellite data for 5 Peruvian samples to compare MOI estimates
491 using microsatellite genotyping and PvAmpSeq. Three out of the five samples appeared to be polyclonal by PvAmpSeq,
492 whereas only one sample was previously reported polyclonal by microsatellites (Table S4).

493 **Classifying recurrent infections using identity-by-descent and probabilistic estimates**

494 Paired samples were further analysed to identify whether recurrent infections were genetically homologous or
495 heterologous to the participants' baseline infection in the Solomon Islands trial or the first infection during the
496 Peruvian community cohort study period. Based on IBD estimates, in the Solomon Islands ACT-Radical clinical trial,
497 55.2% (32/58) of recurrent infections could be classified as homologous, while 41.4% (24/58) could be classified as
498 heterologous and 3.4% (2/58) were not easily classified as IBD was between 0.25-0.5 (Figure 5A). In participants who
499 received primaquine (anti-hypnozoite treatment) at baseline, 47.2% (17/36) of recurrent infections were classified as
500 homologous, while 68.2% of recurrent infections (15/22) from individuals treated without primaquine were
501 homologous (two-sided Fisher's exact test, $p = 0.3202$, Table S5).

502 In the Peruvian community cohort, 23.4% (11/47) of recurrent infections could be classified as homologous, while
503 68.1% (32/47) could be classified as heterologous, and 8.5% (4/47) were not easily classified as IBD was between 0.25-
504 0.5 (Figure 5B). To evaluate whether recurrent polyclonal infections contribute to the increase of IBD, we compared
505 the frequency of heterologous infections in both cohorts per classification group. We did not find an association
506 between MOI and the classification of recurrent infections in both cohorts (two-sided Fisher's exact test, Solomon
507 Islands $p = 0.1279$, Peru $p = 0.3754$; Table S5). Detailed microhaplotype data and classification of recurrent samples
508 can be seen in Text S3 and Text S4.

509 We found that IBD in recurrent infections changed with time for most of the recurrent episodes in both cohorts, with
510 a maximum number of five and three recurrences experienced by the same participant in the Solomon Islands and
511 Peru, respectively (Figure 4B). There was no clear pattern with time to recurrence; for example, we found evidence
512 that the participants in the Solomon Islands clinical trial that had four and five recurrent infections had heterologous
513 and homologous infections compared to the baseline infection, respectively (Figure 4C) and in Peru, most participants
514 experienced heterologous recurrences (Figure 4D).




**Figure 4.** Classification of *Plasmodium vivax* recurrent infections with PvAmpSeq using IBD. (A-B). Distribution of IBD estimates in paired infections from the Solomon Islands and Peru, comparing baseline and recurrent infection pairs. (C-D). IBD between infection pairs in the Solomon Islands and Peru. The X-axis shows the days since baseline or first infection, the Y-axis depicts each patient's infection over time, and the colour represents the IBD estimate range for the infection pairs. Baseline and first infections (Day 0) are not displayed for easier interpretation of plots.

We also performed probabilistic classification of recurrences using the *Pv3Rs* R package and estimated both marginal and joint probability estimates of a recurrent infection being either a relapse, recrudescence, or reinfection to provide further granularity on probable recurrence classification. In Solomon Islands, we explored the most probable classification of the first recurrent infection after treatment and found that 50% of participants experienced a reinfection (mean posterior probability of estimates 0.82, range: 0.51-0.82), 25% experienced a recrudescence (mean posterior probability of estimates 0.75, range: 0.63-0.75) and 25% experienced a potential relapse (mean posterior probability of estimates 0.90, range: 0.62-0.90) (Figure 5A). In the case of participants who experienced more than one recurrence, the trends were less clear (Figure 5A), with some experiencing both reinfection and relapses (e.g., AR-024). Interestingly, for this participant, the IBD estimates for recurrences were all <0.25 compared to baseline, but the

probabilistic estimates pointed to the possibility of both reinfection and relapse over time. A sensitivity analysis using simulated reinfection Solomon Islands data showed a mean FDR (proportion of simulated reinfections being misclassified as relapses or recrudescences) of 4.1% (95% CI: 3.4-4.9%) for the Pv3Rs model.




**Figure 5.** Model-based classification of recurrent *P. vivax* infections with PvAmpSeq. Marginal posterior probability estimates of classification outcome (relapse, recrudescence, or reinfection) of recurrent infections compared to the baseline infection faceted by each participant in (A) the Solomon Islands and (B) Peru. The X-axis shows the episode number; for example, considering that the baseline infection is the first episode, the first recurrent infection would be episode 2.

In Peru, we found that 72.5% of participants likely experienced a reinfection (mean posterior probability of estimates 0.81, range: 0.63-0.81), 27.5% experienced a potential relapse (mean posterior probability of estimates 0.73, range: 0.54-0.73), and none experienced recrudescence (Figure 5B). Most participants experiencing more than one recurrence most likely experienced reinfections (mean posterior probability estimate 0.88, range: 0.65-0.88). For the Peru dataset, our sensitivity analysis showed a mean FDR of 12.4% (95% CI: 11.3-13.4%) for the Pv3Rs model.

We explored whether the exclusion of specific markers may lead to discrepant classification and found little evidence and no clear trend for either the Solomon Islands or Peru datasets, suggesting that the marker panel is robust in different settings (Figure S8). Overall, we found moderate concordance between IBD estimate ranges and probabilistic classification results (Figure S9), with the classification of homologous infections using IBD ranges also found to be either recrudescence or relapses and similarly, heterologous infections were associated with reinfections (Figure S9A-B). This was also consistent with the microhaplotype-specific data for recurrent infections (Figure S10).

549 # Discussion

550 We developed PvAmpSeq, a targeted amplicon sequencing assay that enables the characterisation of *Plasmodium*
551 *vivax* infections at the clonal level by targeting 11 highly polymorphic microhaplotype markers. The PvAmpSeq assay
552 amplifies field samples with >10 parasites/µL, yielding high-depth coverage (5510 [IQR: 3366-8789] reads) but with
553 less coverage for samples with 1-10 parasites/µL. Both archived dried blood samples and red-blood-cell pellet samples
554 were successfully amplified. The high coverage per marker of PvAmpSeq allows the detection of minority clones at a
555 frequency of >10%. The PvAmpSeq microhaplotype markers comprise loci encoding surface antigens, proteins
556 involved in reticulocyte invasion, enzymes, and proteins of unknown function. As a result of immune selection acting
557 on these loci, their high diversity made them suitable for measuring MOI and for tracking individual clones over the
558 course of natural infections within an individual.[47] Our results show that the PvAmpSeq markers provide high
559 resolution to differentiate between homologous and heterologous recurrent infections. The less polymorphic
560 PvAmpSeq markers of the panel could be suitable for studying diversity and structure between global regions;
561 however, further exploration is needed to validate the assay with samples from various geographical origins and in
562 comparison to other genotyping panels (e.g.,[6,26,27,29,30]).

563 We implemented identity-by-descent (IBD) to classify recurrent infections into homologous and heterologous
564 infections compared to their baseline or first infection pair and modelled the probability that recurrent infections were
565 either relapses, recrudescence, or reinfections using recently developed methods.[44,45] At the end of follow-up,
566 homologous infections represented more than half of recurrent infections in the Solomon Islands clinical trial based
567 on IBD estimates, which was in line with our model estimates, further classifying these recurrences into 16% probable
568 relapses and 26% recrudescences, although the uncertainty around these classification results was wide and recovery
569 of appropriate recrudescence and relapse classification may not be sufficiently robust in the current implementation
570 of Pv3Rs (https://github.com/aimeertaylor/Pv3Rs/). Approximately 23% of recurrent infections in the Peruvian cohort
571 were homologous based on IBD, which was also in line with our model estimates of 26% of recurrences being probable
572 relapses (although, again, with relatively wide uncertainty around these estimates). Our results are consistent with
573 low levels of malaria transmission before the ACT-Radical clinical trial was conducted in the Solomon Islands (James,
574 Obadia *et al*. *under review*), with a corresponding less diverse parasite population. In addition, we expected more
575 moderate transmission levels with possible parasite clonal expansion in both sampled communities, Lupuna and
576 Cahuide, in the Peruvian Amazon, based on previous work using microsatellite genotyping.[31,33,43] Secondly, relapses
577 occurring in patients with low hypnozoite load in their liver are usually clonal, and the relapse parasites are genetically

578 homologous to the parasite from the primary infection.[48,49] Adults in endemic areas are more likely to experience
579 relapse with heterologous parasites due to latent hypnozoites from previous inoculations.[48] In contrast, heterologous
580 recurrences were more frequent in the Peruvian cohort, suggesting they could encompass both relapses arising from
581 heterologous hypnozoites from previous inoculations and new infections.

582 IBD estimates (r^) correlated well with model-based classification for most recurrent infections in Peru and the
583 Solomon Islands, showing the potential application of the PvAmpSeq panel. In the case of discordant results, we were
584 unable to definitively ascertain whether this was due to model misspecifications/limitations or limitations of the
585 current AmpSeq panel. It is likely a combination of both since the PvAmpSeq panel includes 11 microhaplotype markers
586 and thus may not always allow appropriate classification of recurrent *P. vivax* malaria infections. In some cases, more
587 than 11 microhaplotype markers may be required, depending on the circulating parasite population's genetic diversity.
588 In addition, the *dcifer*-based IBD estimates assume no within-host relatedness between clones, which would be
589 violated in the case of *P. vivax* relapses and may impact our estimates; however, simulations by Gerlovina *et al*. showed
590 a relatively robust estimation of IBD even when this assumption is violated.[44] Our simple simulation showed robust
591 classification of Pv3Rs and resulted in a low false discovery rate of relapses and recrudescences for the Solomon Islands
592 clinical trial but above 10% for misclassifications of relapses in Peru. This is in line with the different study designs,
593 where there was a clear 'baseline' infection and rigorous follow-up period in the Solomon Islands trial. However, there
594 may be potential limitations for population-based epidemiological studies where there is no clear 'baseline' infection
595 given ongoing transmission and low treatment rates. A limitation of the current implementation of the Pv3Rs model
596 is that all recurrences are compared to the baseline infection, which is appropriate for clinical trials but less so for
597 observational studies like the Peru dataset. Another challenge for IBD-based and Pv3Rs tools is distinguishing between
598 recrudescence and intermittent patency in peripheral blood in chronic spleen-positive infections, i.e., a person might
599 be continuously infected in the spleen,[50] but parasites (all or particular clones) may only be intermittently detectable
600 in the bloodstream; in particular, in observational studies. Future work could explore refining the model-based
601 estimates by using time-to-event models to generate informative prior estimates, as was done with microsatellite
602 data,[51] and leveraging longitudinal studies with repeated sampling. Development of new models or model extensions
603 may also be needed to robustly classify recurrent infections to account for sequencing error, given the availability of
604 many *P. vivax* amplicon sequencing approaches, but this was beyond the scope of the current study. In the context of
605 newly developed marker panels (i.e., amplicon sequencing, molecular inversion probe, and microhaplotype

606 genotyping panels)[6,26,27,29,30], future work could focus on rigorous benchmarking of these analysis tools to provide
607 guidance for the community (e.g., PGEforge https://mrc-ide.github.io/PGEforge/).

608 Detecting microhaplotypes derived from persistent gametocytes or residual DNA in recurrent infections after
609 artemisinin-combination therapy (ACT) could overestimate treatment failure rates.[52,53] Unlike *P. falciparum*, *P. vivax*
610 gametocytes are commonly detected at densities of <10% of asexual parasites, and in the absence of treatment, the
611 duration of gametocytaemia is 3 days.[54] Our approach aimed for coverage of 10,000 reads per marker per sample,
612 ensuring high sensitivity for detecting minority clones at frequencies of 0.5% within-host, i.e., 50 reads. Our sensitivity
613 analysis showed we can confidently detect microhaplotypes with ≥2% within-host frequency; thus, this approach will
614 likely detect gametocyte microhaplotypes. Interestingly, in the Solomon Islands drug-efficacy clinical trial, no recurrent
615 infections were detected earlier than 28 days post-treatment, and homologous recurrent infections were more
616 frequent in patients treated without primaquine, suggestive of relapses; however, low sample sizes when stratifying
617 by treatment arm limited us from drawing definitive conclusions.

618 A limitation of our study was the number of samples included in the validation of PvAmpSeq. The original ACT-Radical
619 clinical trial involved 374 participants, of whom 307 completed follow-up (James, Obadia *et al*. *under review*), but the
620 low parasite density *P. vivax* infections during follow-up limited the number of paired baseline/follow-up samples
621 available for inclusion in PvAmpSeq validation. This could also show a potential bias of PvAmpSeq to better detect new
622 infections that usually have high parasite density. After data demultiplexing and quality control, the remaining sample
623 size per treatment arm was small; thus, we could not definitely employ molecular correction to conclude the treatment
624 efficacy assessed by PvAmpSeq. Future studies should include larger sample sizes and more paired samples; for
625 example, a recent study by Kleinecke *et al*. showed potential for amplicon sequence microhaplotype-based
626 approaches for informing on recurrences.[6] The sensitivity of detection of minority clones was affected by the lack of
627 use of genetically different *P. vivax* strains for mimicking mixed infections. However, the artificial mixed infection
628 estimated that the limit of detection of minority clones was 10% when we had 10,000 reads and 1% if we had 50,000
629 reads. With these features, the potential applications of PvAmpSeq we envision are i) the study of relapse biology in
630 longitudinal studies, ii) the contribution of hidden parasite biomass in spleen and bone-marrow to relapsing *P. vivax*
631 infections iii) parasite diversity dynamics from human-host to mosquito vector, iv) parasite population diversity within
632 mosquito collected in cross-sectional studies.

633 Likewise, in the Peruvian cohort, some intermediate low-density/submicroscopic infections could have been missed;
634 thus, some of the recurrent infections might not reflect the real infection dynamics in this population. A limitation of
635 PvAmpSeq due to the intermittent release of patent parasites to the bloodstream in spleen-positive infection DNA
636 quality from low parasite density samples represented a challenge for PvAmpSeq as observed in samples with 1-10
637 parasites/µL that were discarded due to low coverage (38% of the Solomon Islands samples and 49% of the Peruvian
638 samples). Selective Whole Genome Amplification (sWGA) has been demonstrated to improve sample coverage in very
639 low *Plasmodium* density samples for AmpSeq or WGS methods.[16–18,27,55] However, this type of treatment to low-density
640 samples could incur amplification biases of the most dominant clone, increase the error rate and raise costs, making
641 it less applicable in low-resources settings.[17,18] Other factors may also influence the applicability of PvAmpSeq, like
642 daily fluctuations in clone densities within infection, which may impede robust longitudinal tracking of clones,
643 particularly minor clones. Although we tested 6 PvAmpSeq markers in paired dried-blood spot and red-blood-cell pellet
644 samples, we were not able to evaluate the complete panel of markers in this sample subset due to limited DNA
645 quantities. Nevertheless, we found that PvAmpSeq performed well on both sample types, albeit with better recovery
646 of the number of microhaplotype variants for some of the markers. PvAmpSeq detected more polyclonal infections
647 than microsatellite genotyping in a small subset of Peruvian samples; however, future studies should include larger
648 sample sizes to evaluate the applicability of PvAmpSeq to quantify polyclonal infections in other settings.

649 AmpSeq has been proposed as a new gold standard for analysing malaria drug clinical trials.[3,12] For *P. falciparum*, five
650 AmpSeq markers have been validated to discern between recrudescences and reinfections.[5] Regardless of the level of
651 endemicity and the cut-off of detection for minority clones (0.1 – 2%), simulation studies showed that the use of 3 to
652 5 polymorphic markers was sufficient to classify *P. falciparum* recurrent infections as recrudescence or reinfections.[12]
653 In *P. vivax* infections, genotyping highly related meiotic sibling progeny present in a relapse may not always be possible
654 when using a limited number of markers. Whole genome sequencing analysis has demonstrated that relapses are
655 meiotic siblings resulting from the same meiotic recombination event, contrary to what microsatellite genotyping
656 classified as identical or clonal.[56] Recent *P. vivax* wide-genome panels of Ampseq markers could potentially address
657 this question[6,26,27,29]; however, increasing marker coverage to 10,000 reads would represent higher costs for labs in
658 low-resource settings. Using PvAmpSeq, we classified heterologous/homologous infections using IBD and calculated
659 posterior probability estimates of recurrences being relapse, recrudescence or reinfections by using the information
660 from 11 microhaplotype markers. We found that this classification using both methods was largely concordant in both

samples from the Solomon Islands clinical trial and the Peruvian community cohort. Nevertheless, simulation studies and/or studies conducted in other epidemiological contexts could inform whether the number of PvAmpSeq markers included in this study would be sufficient for classifying recurrent infections in clinical trials executed in settings with higher endemicity levels of *P. vivax* than in this study.

In conclusion, here we present a new framework to classify *P. vivax* recurrent infections using PvAmpSeq microhaplotype data for molecular correction in drug clinical trials and for studying *P. vivax* relapse biology in longitudinal cohorts, and demonstrate its potential using state-of-the-art analysis methods. We anticipate that this tool can be applied in a wide range of epidemiological studies and clinical trials to fill a pressing need in *P. vivax* genomic epidemiology to better understand relapse epidemiology and support the robust evaluation of clinical efficacy trials.

# References


1. World Health Organisation (2024). World malaria report 2024.

2. Robinson, L.J., Wampfler, R., Betuela, I., Karl, S., White, M.T., Li Wai Suen, C.S., Hofmann, N.E., Kinboro, B., Waltmann, A., Brewster, J., et al. (2015). Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. PLoS Med. *12*, e1001891.

3. World Health Organisation (2021). Informal consultation on methodology to distinguish reinfection from recrudescence in high malaria transmission areas.

4. World Health Organisation (2008). Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations.

5. Gruenberg, M., Lerch, A., Beck, H.P., and Felger, I. (2019). Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs. Sci. Rep. *9*, 17790.

6. Kleinecke, M., Rumaseb, A., Sutanto, E., Trimarsanto, H., Hoon, K.S., Osborne, A., Manrique, P., Peters, T., Hawkes, D., Benavente, E.D., et al. (2024). Microhaplotype deep sequencing assays to capture*Plasmodium vivax*infection lineages. medRxiv, 2024.10.14.24315131. https://doi.org/10.1101/2024.10.14.24315131.

7. Lerch, A., Koepfli, C., Hofmann, N.E., Messerli, C., Wilcox, S., Kattenberg, J.H., Betuela, I., O'Connor, L., Mueller, I., and Felger, I. (2017). Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. BMC Genomics *18*, 864.

8. Ruybal-Pesántez, S., McCann, K., Vibin, J., Siegel, S., Auburn, S., and Barry, A.E. (2024). Molecular markers for malaria genetic epidemiology: progress and pitfalls. Trends Parasitol. *40*, 147–163.

9. Lerch, A., Koepfli, C., Hofmann, N.E., Kattenberg, J.H., Rosanas-Urgell, A., Betuela, I., Mueller, I., and Felger, I. (2019). Longitudinal tracking and quantification of individual Plasmodium falciparum clones in complex infections. Sci. Rep. *9*, 3333.

10. Lin, J.T., Hathaway, N.J., Saunders, D.L., Lon, C., Balasubramanian, S., Kharabora, O., Gosi, P., Sriwichai, S., Kartchner, L., Chuor, C.M., et al. (2015). Using Amplicon Deep Sequencing to Detect Genetic Signatures of Plasmodium vivax Relapse. J. Infect. Dis. *212*, 999–1008.

11. Wamae, K., Ndwiga, L., Kharabora, O., Kimenyi, K., Osoti, V., De Laurent, Z.R., Wambua, J., Musyoki, J., Ngetsa, C., Kalume, P., et al. (2022). Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial [version 2; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Res. *7:95*. https://doi.org/10.12688/wellcomeopenres.17736.2.

12. Jones, S., Kay, K., Hodel, E.M., Gruenberg, M., Lerch, A., Felger, I., and Hastings, I. (2021). Should Deep-Sequenced Amplicons Become the New Gold Standard for Analyzing Malaria Drug Clinical Trials? Antimicrob. Agents Chemother. *65*, e0043721.

13. He, X., Zhong, D., Zou, C., Pi, L., Zhao, L., Qin, Y., Pan, M., Wang, S., Zeng, W., Xiang, Z., et al. (2021). Unraveling the Complexity of Imported Malaria Infections by Amplicon Deep Sequencing. Front. Cell. Infect. Microbiol. *11*, 725859.

14. Wamae, K., Kimenyi, K.M., Osoti, V., de Laurent, Z.R., Ndwiga, L., Kharabora, O., Hathaway, N.J., Bailey, J.A., Juliano, J.J., Bejon, P., et al. (2022). Amplicon Sequencing as a Potential Surveillance Tool for Complexity of Infection and Drug Resistance Markers in Plasmodium falciparum Asymptomatic Infections. J. Infect. Dis. *226*, 920–927.

15. Holzschuh, A., Lerch, A., Fakih, B.S., Aliy, S.M., Ali, M.H., Ali, M.A., Bruzzese, D.J., Yukich, J., Hetzel, M.W., and Koepfli, C. (2024). Using a mobile nanopore sequencing lab for end-to-end genomic surveillance of Plasmodium falciparum: A feasibility study. PLOS Glob. Public Health *4*, e0002743.

16. LaVerriere, E., Schwabl, P., Carrasquilla, M., Taylor, A.R., Johnson, Z.M., Shieh, M., Panchal, R., Straub, T.J., Kuzma, R., Watson, S., et al. (2022). Design and implementation of multiplexed amplicon sequencing panels to serve genomic epidemiology of infectious disease: A malaria case study. Mol. Ecol. Resour. *22*, 2285–2303.

17. Kattenberg, J.H., Van Dijk, N.J., Fernandez-Minope, C.A., Guetens, P., Mutsaers, M., Gamboa, D., and Rosanas-Urgell, A. (2023). Molecular Surveillance of Malaria Using the PF AmpliSeq Custom Assay for Plasmodium falciparum Parasites from Dried Blood Spot DNA Isolates from Peru. Bio Protoc. *13*, e4621.

18. Kattenberg, J.H., Fernandez-Minope, C., van Dijk, N.J., Llacsahuanga Allcca, L., Guetens, P., Valdivia, H.O., Van Geertruyden, J.P., Rovira-Vallbona, E., Monsieurs, P., Delgado-Ratto, C., et al. (2023). Malaria Molecular Surveillance in the Peruvian Amazon with a Novel Highly Multiplexed Plasmodium falciparum AmpliSeq Assay. Microbiol. Spectr. *11*, e0096022.

19. Talundzic, E., Ravishankar, S., Kelley, J., Patel, D., Plucinski, M., Schmedes, S., Ljolje, D., Clemons, B., Madison-Antenucci, S., Arguin, P.M., et al. (2018). Next-generation sequencing and bioinformatics protocol for malaria drug resistance marker surveillance. Antimicrob. Agents Chemother. *62*. https://doi.org/10.1128/AAC.02474-17.

20. Huwe, T., Kibria, M.G., Johora, F.T., Phru, C.S., Jahan, N., Hossain, M.S., Khan, W.A., Price, R.N., Ley, B., Alam, M.S., et al. (2022). Heterogeneity in prevalence of subclinical Plasmodium falciparum and Plasmodium vivax infections but no parasite genomic clustering in the Chittagong Hill Tracts, Bangladesh. Malar. J. *21*, 218.

21. Wei, X., Malla, P., Wang, Z., Yang, Z., Cao, Y., Wang, C., and Cui, L. (2024). Genetic diversity of Plasmodium vivax population in northeast Myanmar assessed by amplicon sequencing of PvMSP1 and PvMSP3α. Acta Trop. *260*, 107461.

22. Tapaopong, P., da Silva, G., Holzschuh, A., Rungsarityotin, W., Suansomjit, C., Pumchuea, K., Manopwisedjaroen, K., Khamsiriwatchara, A., Khuntong, P., Cui, L., et al. (2025). Molecular epidemiology and genetic diversity of disappearing Plasmodium vivax in southern Thailand. Sci. Rep. *15*, 2620.

23. Reda, A.G., Huwe, T., Koepfli, C., Assefa, A., Tessema, S.K., Messele, A., Golassa, L., and Mamo, H. (2023). Amplicon deep sequencing of five highly polymorphic markers of Plasmodium falciparum reveals high parasite genetic diversity and moderate population structure in Ethiopia. Malar. J. *22*, 376.

24. Tapaopong, P., da Silva, G., Chainarin, S., Suansomjit, C., Manopwisedjaroen, K., Cui, L., Koepfli, C., Sattabongkot, J., and Nguitragool, W. (2023). Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and Merozoite Surface Protein-1 in northwestern Thailand. Infect. Genet. Evol. *113*,

743 105467.

744 25. Holzschuh, A., Lerch, A., Gerlovina, I., Fakih, B.S., Al-Mafazy, A.-W.H., Reaves, E.J., Ali, A., Abbas, F., Ali, M.H., Ali,
745 M.A., et al. (2023). Multiplexed ddPCR-amplicon sequencing reveals isolated Plasmodium falciparum
746 populations amenable to local elimination in Zanzibar, Tanzania. Nat. Commun. *14*, 3699.

747 26. Siegel, S.V., Trimarsanto, H., Amato, R., Murie, K., Taylor, A.R., Sutanto, E., Kleinecke, M., Whitton, G., Watson,
748 J.A., Imwong, M., et al. (2024). Lineage-informative microhaplotypes for recurrence classification and spatio-
749 temporal surveillance of Plasmodium vivax malaria parasites. Nat. Commun. *15*, 6757.

750 27. Kattenberg, J.H., Nguyen, H.V., Nguyen, H.L., Sauve, E., Nguyen, N.T.H., Chopo-Pizarro, A., Trimarsanto, H.,
751 Monsieurs, P., Guetens, P., Nguyen, X.X., et al. (2022). Novel highly-multiplexed AmpliSeq targeted assay for
752 Plasmodium vivax genetic surveillance use cases at multiple geographical scales. Front. Cell. Infect. Microbiol.
753 *12*, 953187.

754 28. Kattenberg, J.H., Cabrera-Sosa, L., Figueroa-Ildefonso, E., Mutsaers, M., Monsieurs, P., Guetens, P., Infante, B.,
755 Delgado-Ratto, C., Gamboa, D., and Rosanas-Urgell, A. (2024). Plasmodium vivax genomic surveillance in the
756 Peruvian Amazon with Pv AmpliSeq assay. PLoS Negl. Trop. Dis. *18*, e0011879.

757 29. Popkin-Hall, Z.R., Niaré, K., Crudale, R., Simkin, A., Fola, A.A., Sanchez, J.F., Pannebaker, D.L., Giesbrecht, D.J.,
758 Kim, I.E., Jr, Aydemir, Ö., et al. (2024). High-throughput genotyping of Plasmodium vivax in the Peruvian
759 Amazon via molecular inversion probes. Nat. Commun. *15*, 10219.

760 30. Hubbard, A., Solares, E., Bradley, L., Jeang, B., Yewhalaw, D., Janies, D., Lo, E., Yan, G., and Hemming-Schroeder,
761 E. (2025). PvGAP: Development of a globally-applicable, highly-multiplexed microhaplotype amplicon panel for
762 Plasmodium vivax. medRxiv. https://doi.org/10.1101/2025.04.30.25326751.

763 31. Rosado, J., White, M.T., Longley, R.J., Lacerda, M., Monteiro, W., Brewster, J., Sattabongkot, J., Guzman-
764 Guzman, M., Llanos-Cuentas, A., Vinetz, J.M., et al. (2021). Heterogeneity in response to serological exposure
765 markers of recent Plasmodium vivax infections in contrasting epidemiological contexts. PLoS Negl. Trop. Dis. *15*,
766 e0009165.

767 32. Han, J., Munro, J.E., and Bahlo, M. (2023). AmpSeqR: an R package for amplicon deep sequencing data analysis
768 [version 1; peer review: awaiting peer review]. F1000Res. *12*.
769 https://doi.org/10.12688/f1000research.129581.1.

770 33. Rosas-Aguirre, A., Guzman-Guzman, M., Chuquiyauri, R., Moreno, M., Manrique, P., Ramirez, R., Carrasco-
771 Escobar, G., Rodriguez, H., Speybroeck, N., Conn, J.E., et al. (2021). Temporal and Microspatial Heterogeneity in
772 Transmission Dynamics of Coendemic Plasmodium vivax and Plasmodium falciparum in Two Rural Cohort
773 Populations in the Peruvian Amazon. J. Infect. Dis. *223*, 1466–1477.

774 34. Carrasco-Escobar, G., Miranda-Alban, J., Fernandez-Minope, C., Brouwer, K.C., Torres, K., Calderon, M.,
775 Gamboa, D., Llanos-Cuentas, A., and Vinetz, J.M. (2017). High prevalence of very-low Plasmodium falciparum
776 and Plasmodium vivax parasitaemia carriers in the Peruvian Amazon: insights into local and occupational
777 mobility-related transmission. Malar. J. *16*, 415.

778 35. Mangold, K.A., Manson, R.U., Koay, E.S., Stephens, L., Regner, M., Thomson, R.B., Jr, Peterson, L.R., and Kaul,
779 K.L. (2005). Real-time PCR for detection and identification of Plasmodium spp. J. Clin. Microbiol. *43*, 2435–2440.

780 36. Rosanas-Urgell, A., Mueller, D., Betuela, I., Barnadas, C., Iga, J., Zimmerman, P.A., del Portillo, H.A., Siba, P.,
781 Mueller, I., and Felger, I. (2010). Comparison of diagnostic methods for the detection and quantification of the
782 four sympatric Plasmodium species in field samples from Papua New Guinea. Malar. J. *9*, 361.

783 37. Pearson, R.D., Amato, R., Auburn, S., Miotto, O., Almagro-Garcia, J., Amaratunga, C., Suon, S., Mao, S.,
784 Noviyanti, R., Trimarsanto, H., et al. (2016). Genomic analysis of local variation and recent evolution in
785 Plasmodium vivax. Nat. Genet. *48*, 959–964.

786 38. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and
787 Genome Project Data Processing, Subgroup (2009). The Sequence Alignment/Map format and SAMtools.

788 Bioinformatics *25*, 2078–2079.

789 39. Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm, M., and Rozen, S.G. (2012). Primer3--
790 new capabilities and interfaces. Nucleic Acids Res. *40*, e115.

791 40. Pagès, H., Aboyoun, P., Gentleman, R., and DebRoy, S. (2024). Biostrings: Efficient manipulation of biological
792 strings. R package version 2.72.1.

793 41. Morgan, M., Anders, S., Lawrence, M., Aboyoun, P., Pages, H., and Gentleman, R. (2009). ShortRead: a
794 bioconductor package for input, quality assessment and exploration of high-throughput sequence data.
795 Bioinformatics *25*, 2607–2608.

796 42. Havryliuk, T., and Ferreira, M.U. (2009). A closer look at multiple-clone Plasmodium vivax infections: detection
797 methods, prevalence and consequences. Mem. Inst. Oswaldo Cruz *104*, 67–73.

798 43. Manrique, P., Miranda-Alban, J., Alarcon-Baldeon, J., Ramirez, R., Carrasco-Escobar, G., Herrera, H., Guzman-
799 Guzman, M., Rosas-Aguirre, A., Llanos-Cuentas, A., Vinetz, J.M., et al. (2019). Microsatellite analysis reveals
800 connectivity among geographically distant transmission zones of Plasmodium vivax in the Peruvian Amazon: A
801 critical barrier to regional malaria elimination. PLoS Negl. Trop. Dis. *13*, e0007876.

802 44. Gerlovina, I., Gerlovin, B., Rodriguez-Barraquer, I., and Greenhouse, B. (2022). Dcifer: an IBD-based method to
803 calculate genetic distance between polyclonal infections. Genetics *222*.
804 https://doi.org/10.1093/genetics/iyac126.

805 45. Taylor, A.R., Foo, Y.S., and White, M.T. (2022). *Plasmodium vivax*relapse, reinfection and recrudescence
806 estimation using genetic data. bioRxiv, 2022.11.23.22282669. https://doi.org/10.1101/2022.11.23.22282669.

807 46. Meacham, F., Boffelli, D., Dhahbi, J., Martin, D.I., Singer, M., and Pachter, L. (2011). Identification and correction
808 of systematic error in high-throughput sequence data. BMC Bioinformatics *12*, 451.

809 47. Barry, A.E., Waltmann, A., Koepfli, C., Barnadas, C., and Mueller, I. (2015). Uncovering the transmission
810 dynamics of Plasmodium vivax using population genetics. Pathog. Glob. Health *109*, 142–152.

811 48. Imwong, M., Boel, M.E., Pagornrat, W., Pimanpanarak, M., McGready, R., Day, N.P., Nosten, F., and White, N.J.
812 (2012). The first Plasmodium vivax relapses of life are usually genetically homologous. J. Infect. Dis. *205*, 680–
813 683.

814 49. Chen, N., Auliff, A., Rieckmann, K., Gatton, M., and Cheng, Q. (2007). Relapses of Plasmodium vivax infection
815 result from clonal hypnozoites activated at predetermined intervals. J. Infect. Dis. *195*, 934–941.

816 50. Kho, S., Qotrunnada, L., Leonardo, L., Andries, B., Wardani, P.A.I., Fricot, A., Henry, B., Hardy, D., Margyaningsih,
817 N.I., Apriyanti, D., et al. (2021). Hidden biomass of intact malaria parasites in the human spleen. N. Engl. J. Med.
818 *384*, 2067–2069.

819 51. Taylor, A.R., Watson, J.A., Chu, C.S., Puaprasert, K., Duanguppama, J., Day, N.P.J., Nosten, F., Neafsey, D.E.,
820 Buckee, C.O., Imwong, M., et al. (2019). Resolving the cause of recurrent Plasmodium vivax malaria
821 probabilistically. Nat. Commun. *10*, 5595.

822 52. Hasugian, A.R., Purba, H.L., Kenangalem, E., Wuwung, R.M., Ebsworth, E.P., Maristela, R., Penttinen, P.M.,
823 Laihad, F., Anstey, N.M., Tjitra, E., et al. (2007). Dihydroartemisinin-piperaquine versus artesunate-
824 amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium
825 falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. *44*, 1067–1074.

826 53. Pukrittayakamee, S., Imwong, M., Singhasivanon, P., Stepniewska, K., Day, N.J., and White, N.J. (2008). Effects of
827 different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am. J. Trop. Med. Hyg. *79*, 378–384.

828 54. Bousema, T., and Drakeley, C. (2011). Epidemiology and infectivity of Plasmodium falciparum and Plasmodium
829 vivax gametocytes in relation to malaria control and elimination. Clin. Microbiol. Rev. *24*, 377–410.

830 55. Oyola, S.O., Ariani, C.V., Hamilton, W.L., Kekre, M., Amenga-Etego, L.N., Ghansah, A., Rutledge, G.G., Redmond,

S., Manske, M., Jyothi, D., et al. (2016). Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification. Malar. J. *15*, 597.

56. Bright, A.T., Manary, M.J., Tewhey, R., Arango, E.M., Wang, T., Schork, N.J., Yanow, S.K., and Winzeler, E.A. (2014). A high resolution case study of a patient with recurrent Plasmodium vivax infections shows that relapses were caused by meiotic siblings. PLoS Negl. Trop. Dis. *8*, e2882.

# Acknowledgments

We thank the participants who anonymously agreed to participate in the ACT-Radical clinical trial and the ICEMR study. We acknowledge the field teams that contributed to sample collection in Solomon Islands and Peru, and Soazic Gardais for logistical support at Institut Pasteur Paris. We thank Leanne Robinson for provision of the control DNA samples. We thank Aimee Taylor for her input and advice on running Pv3Rs. This work was also made possible through the Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme.

# Author's contributions

JR, IM, and SRP designed the study. JR and SRP designed PvAmpSeq protocols. ZT, KS, JB and CB did the genotyping. JH, JM, and MB developed AmpSeqR and preprocessed sequencing data, with contributions from JR, SRP, and CB. JR and SRP analysed the data and performed statistical analyses. JMV, MTW, MB, DG, and IM provided administrative and logistical support. JR and SRP wrote the first draft of the manuscript. All authors had full access to all the data. All authors contributed to the manuscript's writing.

# Declaration of interest

The authors declare no conflicts of interest.

# Funding

The study was supported by a grant from the Bill and Melinda Gates Foundation (funding grant ID number: OPP1151132). IM was supported by an Australian National Health and Medical Research Council (NHMRC) Investigator Grant (#2016726). MB was supported by an Australian NHMRC Investigator Grant (GNT1195236). The Peruvian cohort was part of the Amazonian International Center of Excellence in Malaria Research that received funding through the Cooperative Agreement U19AI089681 from the US Public Health Service, National Institutes of Health/National Institute of Allergy and Infectious Diseases, USA to JMV, and from a FOGARTY global infectious disease training grant (2D43TW007120-11A1, NIH-USA to JMV). JR postdoctoral fellowship was funded by Institut de Recherche pour le Développement. SR-P acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/X020258/1), funded by the UK Medical Research Council (MRC). This UK-funded award is carried out in the frame of the Global Health EDCTP3 Joint Undertaking.

# Supplemental information

Document S1. Figures S1–S10

Document S2. Table S1–S5

Text S1. Detailed standard operational protocols for PvAmpSeq.

Text S2. Excel file containing additional data on PvAmpSeq markers, too large to fit in a PDF.

Text S3. Data of IBD classification in Solomon Islands cohort.

Text S4. Data of IBD classification in the Peruvian cohort.